RVL Pharmaceuticals (RVL Pharmaceuticals) FCF Yield % : -84,794.64 (As of May. 31, 2024)

View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, RVL Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-47.49 Mil, and Market Cap is $0.06 Mil. Therefore, RVL Pharmaceuticals's FCF Yield % for today is -84,794.64%.

The historical rank and industry rank for RVL Pharmaceuticals's FCF Yield % or its related term are showing as below:

RVLPQ' s FCF Yield % Range Over the Past 10 Years
Min: -477860.52 Med: -7.62 Max: 28.42
Current: -84794.64

During the past 7 years, the highest FCF Yield % of RVL Pharmaceuticals was 28.42%. The lowest was -477860.52%. And the median was -7.62%.

RVLPQ's FCF Yield % is ranked worse than
99.87% of 1552 companies
in the Biotechnology industry
Industry Median: -14.35 vs RVLPQ: -84794.64

RVL Pharmaceuticals's FCF Margin % for the quarter that ended in Jun. 2023 was -158.73%.

RVL Pharmaceuticals FCF Yield % Historical Data

The historical data trend for RVL Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals FCF Yield % Chart

RVL Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Yield %

Get a 7-Day Free Trial

8.21

8.15

5.61

-62.82

-34.72

RVL Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
FCF Yield %	Get a 7-Day Free Trial															7.02	-19.44	-61.71	-25.15	-94.18

Competitive Comparison of RVL Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, RVL Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RVL Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's FCF Yield % falls into.

RVL Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

RVL Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-38.562	/	111.060768
	=	-34.72%

RVL Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-13.108	*	4	/	55.66957122
	=	-94.18%

RVL Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

RVL Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

RVL Pharmaceuticals (RVL Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (OTCPK:RVLPQ) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Crossing Boulevard, Bridgewater, NJ, USA, 08807

Website

https://www.rvlpharma.com

RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

Executives

Foundation Harsaul	10 percent owner	EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1
Altchem Ltd	10 percent owner	KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032
Alisa Lask	director	C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Athyrium Opportunities Associates Iv Co-invest Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Gp Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Co-invest 2 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Acquisition 2 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Funds Gp Holdings Llc	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Avista Healthcare Partners, L.p.	10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Brian A Markison	director, officer: Chief Executive Officer	501 FIFTH STREET, BRISTOL TN 37620
Sriram Venkataraman	director, 10 percent owner	C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jeffrey Ferrell	10 percent owner	ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017
James Schaub	officer: EVP and COO	400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807